OBiO Tech(SH:688238) Ge Long Hui·2025-07-29 09:00Core Viewpoint - The company, He Yuan Biology, is making significant advancements in CAR-T therapy, a cutting-edge cell immunotherapy that modifies patients' T cells to target cancer cells effectively [1] Group 1: Technological Advancements - The company has achieved a 90% positive rate in the transduction of NK cells using optimized lentiviral vector technology, overcoming challenges in the production process [1] - Improvements in CAR-T related lentiviral vector yield have been made through sequence optimization and the replacement of traditional RSV promoters with preferred promoters [1] - The establishment of an mRNA CAR-T electroporation platform has been successfully completed, along with breakthroughs in enhanced CAR-T project processes [1] Group 2: Strategic Collaborations - The company has formed strategic partnerships to develop advanced technologies in in-vivo CAR-T therapies, including mRNA-LNP non-viral vector technologies [1] - Extensive platform technology research and development has led to the establishment of the T-Flash short-term autologous CAR-T process, which is being applied to client IND projects [1] Group 3: Regulatory Achievements - As of Q1 2025, the company has assisted clients in obtaining multiple domestic and international IND approvals for various product types, including CAR-T, Treg, and stem cell therapies [1]